NKTR painted a pretty bleak picture for this year, however, I think they were projecting income based on Pfizers figures. I might be wrong but I think once this product hits the market we will have another Lipitor. I know all the hype about transdermal insulin, my thoughts are, if skin could absorb insulin in a manner necessary to affect blood sugar, someone would of discoverd that a long time ago.
I think NKTR was simply oversold and the market is bringing it back to its potential around $22.00.
